Plasma Industry is expected to grow at a CAGR of 10.54% between the years 2015-2020.
The total global plasma collections totals to about 36.8mn liters (2014) and is expected to reach about 50 million liters by 2020.
Although Asia houses about 60% of the world’s population, it has only 20% of the global plasma fractionation capacity - a huge imbalance which will be one of the key drivers of growth of the plasma products in the coming years in Asia. The improved indicators of growing Asian economy, has made it the cynosure of Global Plasma Fractionation Industry.
India harbors a network of 2700 blood banks and accounts for 10% of the world’s blood collection (10 million units); but due to only ~40% of blood being subjected to componentization and absence of source plasma collection, very limited amount of plasma is available for fractionation.
For a country that accounts for almost 18% of the world’s population(1.32bn people), making up merely 1.3 % of the world’s total plasma collection is not only ironic but also indicates towards a huge existing gap between the demand of plasma, needed for providing safe plasma products and its truncated supply, mainly due to underutilization of its resources and regulatory system.
It needs an integrated inclusive model of plasma protein therapy which includes: proper channel for collection of plasma,policy amendments for the collection of source plasma, contract fractionation and an increase in plasma fractionation capacity in the country.
With a huge growing population in SAARC region, the disease burden is also on rise and puts a very heavy stress on the healthcare system and its various components. For manufacturing plasma proteins; this region is dependent only on recovered plasma, as source plasma collection for plasma fractionation is not included in the regulatory guidelines. Furthermore, within this region the rate of blood donation is fairly low and largely dependent on one time donation; and to add to this quandary, rampant whole blood therapy, further limits the availability of safe plasma for fractionation.
But as this region is also on the path of economic prosperity, it holds a huge potential to grow in this domain. Affordability apart, the key challenge is timely and uninterrupted availability of safe plasma products. As the socioeconomic condition of SAARC is different within Asia itself, a unique sustainable model of Plasma Fractionation Industry is needed to make it socially relevant and financially viable.